MedTrace Logo

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

NCT06200181 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2026-02-13

No results posted yet for this study

Summary

To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.

Conditions

  • Misuse, Opioid

Interventions

DRUG

Olanzapine

Given by PO

DRUG

Olanzapine

Given by PO

DRUG

Placebo

Given by PO

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Joseph Arthur, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-02
Primary Completion
2026-11-01
Completion
2026-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200181 on ClinicalTrials.gov